Rivaroxaban (Xarelto®) for Atrial Fibrillation patients undergoing PCI

Assessment Status Rapid Review Complete
Drug Rivaroxaban
Brand Xarelto®
Indication Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.
Assessment Process
Rapid review commissioned 20/11/2017
Rapid review completed 21/11/2017
Rapid review outcome Full Pharmacoeconomic Assessment Recommended

A full pharmacoeconomic evaluation is not required as rivaroxaban 10mg is reimbursable under the Community Drug Schemes.